These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34613603)

  • 1. Belzutifan: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
    N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
    Curry L; Soleimani M
    Future Oncol; 2024; 20(18):1251-1266. PubMed ID: 38639572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
    Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
    Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
    Iliopoulos O; Iversen AB; Narayan V; Maughan BL; Beckermann KE; Oudard S; Else T; Maranchie JK; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R; Jonasch E
    Lancet Oncol; 2024 Oct; 25(10):1325-1336. PubMed ID: 39284337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
    Hasanov E; Jonasch E
    Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
    Shepherd STC; Drake WM; Turajlic S
    Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
    Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
    Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma.
    Rioja P; Rey-Cardenas M; De Velasco G
    Cancer Treat Rev; 2024 Sep; 129():102801. PubMed ID: 39032449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling.
    Marathe DD; Jauslin PM; Jan Kleijn H; De Miranda Silva C; Chain A; Abraham AK; Kauh EA; Liu Y; Perini RF; Alwis DP; Jain L
    J Clin Pharmacol; 2024 Oct; 64(10):1246-1258. PubMed ID: 38752556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
    Pelle E; Al-Toubah T; Morse B; Strosberg J
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belzutifan: A Narrative Drug Review.
    Visweswaran V; Pavithran K
    Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
    Choi WW; Boland JL; Kalola A; Lin J
    Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
    Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
    J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
    Yu Y; Yu Q; Zhang X
    Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
    Suárez C; Vieito M; Valdivia A; González M; Carles J
    Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
    Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
    Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: A systematic review and single-arm meta-analysis.
    Palavani LB; Camerotte R; Vieira Nogueira B; Ferreira MY; Oliveira LB; Pari Mitre L; Coelho Nogueira de Castro W; Canto Gomes GL; Fabrini Paleare LF; Batista S; Fim Andreão F; Bertani R; Dias Polverini A
    J Clin Neurosci; 2024 Oct; 128():110774. PubMed ID: 39128437
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ren X; Diao X; Zhuang J; Wu D
    Mol Pharmacol; 2022 Sep; ():. PubMed ID: 36167425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.